Details of the Drug Combination

General Information of Drug Combination (ID: DC4VVK8)

Drug Combination Name

IT-141 GSK2194069

Indication

Disease Entry	Status	REF
Chronic myelogenous leukemia	Investigative	[1]

Component Drugs

IT-141 DMAYD7O

GSK2194069 DMZ2TD9

N.A.

Small molecular drug

High-throughput Screening Result

Testing Cell Line: KBM-7

Zero Interaction Potency (ZIP) Score: 4.86

Bliss Independence Score: 4.86

Loewe Additivity Score: 5.17

LHighest Single Agent (HSA) Score: 5.25

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of IT-141

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

IT-141 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase I (TOP1)	TTGTQHC	TOP1_HUMAN	Inhibitor	[2]
------------------------------------------------------------------------------------

Indication(s) of GSK2194069

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[3]

GSK2194069 Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Fatty acid synthase (FASN)	TT7AOUD	FAS_HUMAN	Inhibitor	[3]
------------------------------------------------------------------------------------

References

1	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014 Sep;10(9):774-9.